Jounce Therapeutics Inc (NASDAQ:JNCE) insider Elizabeth Trehu sold 4,545 shares of Jounce Therapeutics stock in a transaction on Thursday, March 8th. The shares were sold at an average price of $25.06, for a total value of $113,897.70. Following the transaction, the insider now owns 4,545 shares in the company, valued at $113,897.70. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Elizabeth Trehu also recently made the following trade(s):
- On Monday, March 5th, Elizabeth Trehu sold 4,545 shares of Jounce Therapeutics stock. The stock was sold at an average price of $21.50, for a total value of $97,717.50.
Shares of Jounce Therapeutics Inc (JNCE) opened at $27.01 on Tuesday. Jounce Therapeutics Inc has a one year low of $11.05 and a one year high of $29.29.
JNCE has been the subject of several research reports. Zacks Investment Research lowered Jounce Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 17th. Robert W. Baird set a $35.00 price objective on Jounce Therapeutics and gave the stock a “buy” rating in a research note on Thursday, March 8th. Finally, JPMorgan Chase & Co. set a $28.00 price objective on Jounce Therapeutics and gave the stock a “buy” rating in a research note on Monday, November 13th.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Macquarie Group Ltd. bought a new stake in shares of Jounce Therapeutics during the 3rd quarter worth $124,000. Rhumbline Advisers bought a new stake in shares of Jounce Therapeutics during the 4th quarter worth $134,000. American International Group Inc. boosted its stake in shares of Jounce Therapeutics by 132.2% during the 3rd quarter. American International Group Inc. now owns 9,559 shares of the company’s stock worth $149,000 after acquiring an additional 5,442 shares in the last quarter. Teachers Advisors LLC boosted its stake in shares of Jounce Therapeutics by 26.4% during the 2nd quarter. Teachers Advisors LLC now owns 11,231 shares of the company’s stock worth $158,000 after acquiring an additional 2,347 shares in the last quarter. Finally, Ark Investment Management LLC boosted its position in shares of Jounce Therapeutics by 558.9% in the second quarter. Ark Investment Management LLC now owns 11,932 shares of the company’s stock worth $167,000 after buying an additional 10,121 shares during the period. 90.81% of the stock is owned by institutional investors and hedge funds.
About Jounce Therapeutics
Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.